Author: Groeneveld, Geert H; van der Reyden, Tanny J; Joosten, Simone A; Bootsma, Hester J; Cobbaert, Christa M; de Vries, Jutte J C; Kuijper, Ed J; van Dissel, Jaap T
Title: Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial Document date: 2019_5_18
ID: 19ueli6e_50
Snippet: The PRISTINE study is the first exploratory clinical trial in humans to determine the feasibility of adding rifampicin to standard treatment with b-lactams for patients with community-acquired pneumococcal pneumonia. The rifampicin is added to reduce the release of bacterial compounds within the first hours of therapy and thereby attenuate the inflammatory response. In this initial small group, the b-lactam antibiotic with additional non-lytic ri.....
Document: The PRISTINE study is the first exploratory clinical trial in humans to determine the feasibility of adding rifampicin to standard treatment with b-lactams for patients with community-acquired pneumococcal pneumonia. The rifampicin is added to reduce the release of bacterial compounds within the first hours of therapy and thereby attenuate the inflammatory response. In this initial small group, the b-lactam antibiotic with additional non-lytic rifampicin antibiotic versus lytic b-lactam antibiotic only treatment for pneumococcal pneumonia did not reveal differences in the blood concentrations of various inflammatory biomarkers, nor in the clinical response to treatment.
Search related documents:
Co phrase search for related documents- blood concentration and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- blood concentration and human clinical trial: 1
- blood concentration and inflammatory response: 1, 2, 3, 4, 5, 6, 7
- blood concentration and pneumococcal pneumonia: 1
- blood concentration and standard treatment: 1, 2, 3, 4, 5, 6
- clinical response and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical response and non lytic rifampicin: 1, 2
- clinical response and pneumococcal pneumonia: 1, 2, 3, 4, 5, 6
- clinical response and pneumococcal pneumonia treatment: 1, 2, 3
- clinical response and pristine study: 1, 2
- clinical response and small group: 1, 2
- clinical response and standard treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- clinical response and treatment clinical response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and human clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54
- clinical trial and inflammatory biomarker: 1, 2, 3, 4, 5
- clinical trial and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
- clinical trial and non lytic rifampicin: 1
- clinical trial and pneumococcal pneumonia: 1, 2
- clinical trial and pneumococcal pneumonia treatment: 1
Co phrase search for related documents, hyperlinks ordered by date